Strides Pharma Science Limited — Board Meeting, 29-07-2025: Outcome of Board Meeting

Strides Pharma Science Limited's Board met to approve the financial results for the quarter ended June 30, 2025. The company reported a consolidated revenue from operations of Rs. 1,119.74 Cr and a profit of Rs. 99.61 Cr attributable to owners. Earnings per share stood at Rs. 10.81.

The Board also proposed a final dividend of Rs. 4 per equity share, which is subject to shareholder approval. Additionally, a new strategic demerger was approved in-principle for Arco Lab's identified business into a new subsidiary, Pivot Path Private Limited, with the scheme now filed for NCLT approval. This aims to streamline operations.